On January 5, 2022 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, reported that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022 (Press release, Mannkind, JAN 5, 2022, View Source [SID1234598231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at View Source The webcast replay may be accessed at the same location for 14 days.

On January 5, 2022 Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, reported that the company will participate in the following January investor conferences (Press release, Magenta Therapeutics, JAN 5, 2022, View Source [SID1234598230]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

40th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 13th, 2022, at 9:45 a.m. ET, immediately followed by a Q&A session
B. Riley Virtual Oncology Conference, on Friday, January 28th, 2022, at 11:00 a.m. ET
A live webcast of the presentations can be accessed through the Investors & Media section of Magenta’s website at View Source A replay of each webcast will be available on Magenta’s website for 30 days following the events.

On January 5, 2022 Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that its Chief Executive Officer, Robert E. Hoffman will present at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022 (Press release, Kintara Therapeutics, JAN 5, 2022, View Source [SID1234598227]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on-demand beginning at 7:00 a.m. ET on Monday, January 10, 2022, and will be available for 90 days.

Register to view the presentation:
View Source

On January 5, 2022 Invitae Corporation (NYSE: NVTA), a leading medical genetics company, reported that Sean George, chief executive officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 9:45 a.m. Eastern Time (Press release, Invitae, JAN 5, 2022, View Source [SID1234598225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)

The live audio webcast of the presentation may be accessed by visiting the investors section of the company website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the presentation.

On January 5, 2022 Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, reported that Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the JP Morgan Healthcare Meeting held virtually on January 10-13, 2022 (Press release, Invectys, JAN 5, 2022, View Source [SID1234598223]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the main meeting, Dr. Tyle will also attend Biotech ShowcaseTM, virtually from January 10-19. He will present an overview of all of Invectys’ projects to date on January 11th, at 9:15 am Pacific time. The presentation has already been posted on the Biotech Showcase website.